Other compounds include CA77.1, a synthetic CMA activator, which boosts LAMP2A expression to degrade pathogenic tau and improve cognition in AD animal studies (discussed within [95]), AUTEN-67, an autophagic flux enhancer, exhibits neuroprotection in Drosophila Huntington’s models, suggesting potential cross-application for AD [96], and finally, Humanin, a mitochondrial peptide, which stimulates CMA, counters oxidative stress, and reduces amyloid-beta, positioning it as a multi-target candidate [97]. Here, MAPT is linked to Alzheimer disease.